article thumbnail

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

The Pharma Data

This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives.

article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Bredl’s poster looks at genetically engineered macrophages to disrupt the cold tumour microenvironment, and Sobczak’s covers deciphering the structural details of the recognition mode of cancer-associated glycoproteins by siglec receptors implicated in immune suppression in cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Marine Houdou, Genetic Engineering Specialist, Polyplus, on: ‘From modular DNA assembly to recombinant protein production at Polyplus’. Charlotte Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Chief Scientist, Biologics AI, Exscientia, giving a featured presentation on generative antibody modelling.

article thumbnail

United Therapeutics Corporation Reports Third Quarter 2020 Financial Results

The Pharma Data

the phase 2 SAPPHIRE study seeks to evaluate the use of autologous endothelial progenitor cells (EPCs) genetically engineered to express endothelial nitric oxide synthase in patients with PAH taking conventional PAH treatments. Conducted by our Canadian affiliate Northern Therapeutics, Inc.,